|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
388.20 Million
|
|
CAGR
(2023-2028)
|
25.61%
|
|
Fastest
Growing Segment
|
Pharmaceutical
& Biotechnology Companies
|
|
Largest
Market
|
North
America
|
Market Overview
Global Organ-on-Chip
Market has valued at USD 388.20 million in 2022 and is anticipated to project impressive
growth in the forecast period with a CAGR of 25.61% through 2028. Organs-on-chip
are sophisticated artificial replicas of human organs. These cutting-edge
devices utilize multichannel 3D microfluidic cell culture technology to
faithfully mimic organ functions, processes, and physiological responses. By
combining labs-on-chips (LOCs) with cell biology, researchers have successfully
created a novel model of in vitro multicellular human beings, allowing for the
analysis of human physiology within organ-specific environments.
These chips feature
intricately designed microchannels that facilitate blood and air flow, enabling
the simulation of various organs such as the lung, intestine, brain, liver, and
heart. The microchips are populated with live cells, fostering tissue and organ
function through constant perfusion. Organ-on-chip technology, with its unique
blend of silicone nourishment, tissue engineering, and microfluidics, has the
potential to revolutionize the field. These advancements hold great promise in
addressing longstanding challenges in drug discovery and disease treatment,
making it a crucial component in drug development investigations and propelling
the organ-on-chip industry forward.
Key Market Drivers
Growing
Demand of Miniaturization of Electronic Chips
The growing prevalence for
microchips in the field of medical devices is a direct result of remarkable
technological advancements. These advancements have not only fueled the demand
for such devices but also paved the way for significant improvements in their
construction and maintenance. The process of miniaturization has played a key
role in achieving these advancements, as it allows for the reduction of
materials required to build and sustain the system.
Moreover, the utilization
of microfluidic chips has revolutionized the development of miniaturized
tissues, enabling the simulation of real tissue in organ-on-a-chip systems. By
creating an in vitro environment at the microscopic scale, these microfluidic
chips effectively mimic the function and structure of actual organs. This
breakthrough technology holds tremendous promise in advancing our understanding
of organ function and disease progression. The integration of microchips and
microfluidic chips in medical devices marks a significant milestone in the
field of healthcare. With continued research and innovation, we can expect even
greater advancements in this fascinating area, ultimately leading to improved
diagnostics, treatments, and overall patient care.
Rising
Healthcare Expenditure in Developed Countries
The rising prevalence of
chronic diseases and an expanding elderly patient population are expected to
drive up demand for market growth. The increasing burden of chronic conditions
and the aging population necessitate a greater need for healthcare services and
products. Moreover, rising healthcare expenditures in many countries, driven by
factors such as advancements in medical technologies and an increasing focus on
preventive care, are expected to further fuel the market in the approaching
years. As a result, an exponential increase in the number of patients seeking
treatment is anticipated, leading to a significant surge in product demand over
the projection period.
For instance, in February
2019, a comprehensive report by the World Health Organization (WHO) on global
health expenditure highlighted a rapid upward trajectory in healthcare
spending, particularly noticeable in low and middle-income countries. These regions
have been witnessing an average annual growth rate of 6%, compared to 4% in
high-income countries. This trend underscores the growing recognition of the
importance of healthcare and the need for increased investments to address the
healthcare needs of the population.
With the convergence of
these factors, the market is poised for significant growth, presenting new
opportunities for healthcare providers, innovators, and investors alike.
Increasing
Use an Alternative for Animal Testing
The increasing need for
alternatives to animal testing is driving the growth of the global
organ-on-chip market in the forecast period. Concerns about the ethical
treatment of animals have led to a paradigm shift in scientific research.
According to the People for the Ethical Treatment of Animals (PETA), each year,
more than 110 million animals, including rats, fish, rabbits, dogs, frogs,
monkeys, hamsters, mice, cats, guinea pigs, and birds, are sacrificed in U.S.
laboratories for various purposes such as biology studies, medical internships,
curiosity-driven investigations, and testing of chemicals, pharmaceuticals,
food, and cosmetics.
A Pew Research Center poll
revealed that 52% of U.S. adults oppose the use of animals in scientific
research. Other surveys indicate that the remaining group that supports animal
research does so because they believe it is necessary for medical progress.
However, it is important to note that the majority of animal studies do not
significantly contribute to improving human health. The role that animal
research plays in most medical advancements is a subject of debate and
controversy. These concerns have led to a growing demand for alternative
testing methods, such as organ-on-chip technology. Organ-on-chip devices aim to
replicate the functions of human organs, providing a more accurate and humane
approach to studying diseases and testing potential treatments. As the
awareness and support for alternatives to animal testing continue to rise, the
global organ-on-chip market is expected to witness significant growth in the
coming years.
Integration
of Technologies
The increasing demand for
organ-on-chip technology is primarily driven by its unique combination of
tissue engineering and microfluidics. This innovative approach not only offers
effective solutions to long-standing challenges in individualized disease treatment
and medication discovery but also holds immense potential for revolutionizing
the field of biomedical research. By replicating the complex structures and
functions of human organs, organ-on-chip platforms provide a more accurate and
reliable model for drug development studies. This enables researchers to gain
deeper insights into the efficacy and safety of potential medications, leading
to improved patient outcomes. With its ability to mimic the physiological
conditions of specific organs, organ-on-chip technology allows for personalized
testing and analysis, paving the way for tailored treatment approaches.
Moreover, the versatility
of organ-on-chip technology extends beyond drug development. It holds promise
in various areas of research, such as toxicology studies, disease modeling, and
precision medicine. By simulating the intricate interactions between cells,
tissues, and fluids, organ-on-chip devices enable scientists to investigate
complex biological processes in a controlled and reproducible manner. Overall,
organ-on-chip technology has the potential to transform the way we approach
healthcare. By bridging the gap between traditional in vitro models and animal
testing, it offers a powerful tool for accelerating medical research, improving
drug discovery, and ultimately enhancing patient care.
Download Free Sample Report
Key Market Challenges
Concerns
Pertaining due to High Cost of Organ Chip Device
The high cost associated
with the organ chip device, coupled with the fact that organ-on-chip (OOC)
technology is still in its early stages, is projected to limit the expansion of
the market. This is primarily due to the significant investment required for
research and development, manufacturing, and commercialization of organ-on-chip
devices. The complex nature of the technology, involving the integration of
multiple organ models and microfluidic systems, adds to the manufacturing
challenges and cost considerations.
Furthermore, certain
countries have imposed restrictions on cosmetic testing on animals, which is
likely to further hinder the growth of the global organ-on-chip market. In
these countries, the government has prohibited the use of animals for testing
cosmetics developed within their borders, reflecting a growing awareness and
concern for animal welfare. This shift in regulatory policies has prompted the
need for alternative testing methods, such as organ-on-chip technology, which
can simulate the physiological conditions of human organs and provide more
accurate and ethical results.
These factors collectively
contribute to the complex landscape surrounding the adoption and market
potential of organ-on-chip technology. While the technology holds great promise
for revolutionizing drug discovery, toxicity testing, and personalized medicine,
overcoming the barriers of cost, scale-up, and regulatory requirements remains
crucial for its widespread adoption and market success. Continued advancements
in technology, coupled with collaborative efforts between academia, industry,
and regulatory bodies, will play a vital role in addressing these challenges
and unlocking the full potential of organ-on-chip technology in improving
healthcare outcomes.
Availability
of Substituents
The availability of the
substituent in the market to organ-on-chips is hampering the global market
growth in the forecast period. This is because the availability of organoids,
which serve the same purpose of mimicking tissue and organ physiology, poses a
major hurdle for the organ-on-chip market during this time. Organoids are
gaining traction in the market due to their ability to replicate the complex
structure and functionality of organs, making them a potential alternative to
organ-on-chips.
Furthermore, the
increasing developments in the organoids market are presenting threats to the
global organ-on-chip market in the upcoming forecast years. For instance, on
October 3, 2022, AIM Biotech Pte. Ltd. introduced the organiX System, a
cutting-edge 3D tissue culture platform. This innovative system enables the
addition of vascularization and immune competence to spheroids, tumor biopsies,
and organoids, further enhancing their functionality and applicability.
These advancements in
organoids technology highlight the evolving landscape of tissue engineering and
regenerative medicine, paving the way for more sophisticated and versatile
models. As a result, the organ-on-chip market faces the challenge of keeping up
with these developments and finding unique value propositions to maintain its
competitive edge in the market. While the availability of substitutes like
organoids poses challenges to the organ-on-chip market, the continuous
advancements and innovations in the field of organoids present opportunities
for further growth and improvement in the overall market.
Key Market Trends
Increasing
Market Developments
The organ-on-chip market
is experiencing significant growth due to various market developments such as
product launches, collaborations, mergers, acquisitions, and more. These developments
are driving the global market growth in the forecast period.
For example, in September
2021, Fidia Farmaceutici S.p.A. and BiomimX S.r.l. entered into a research
collaboration aimed at presenting and introducing new specialized solutions
based on Organs-on-Chip to enhance the intra-articular medical device discovery
process.
Furthermore, in November
2021, AIM Biotech introduced its idenTx 40 Plate, a high-throughput
organ-on-a-chip technique. This revolutionary technique enables investigators
at pharmaceutical and biotechnology companies to simulate the operation of
human tissues and organs without the need for animal experimentation, thus
advancing the field of research while upholding ethical standards.
Rapidly
Rising Number of Applications
Microfluidic devices and
organotypic slices have been combined to improve culture survival in the field
of neuroscience research. Traditionally, cultivating organotypic brain slices,
which are approximately 300 microns thick, has relied on semi-porous membranes
to establish an air-medium interface. However, with the integration of
microfluidic technologies, a more sophisticated approach has emerged. These
technologies enable the laminar flow of essential nutrients and gases,
resulting in enhanced tissue viability and improved transportation within the
brain slices.
Furthermore, the advent of
brain-on-a-chip technologies has revolutionized the cultivation of thicker
brain slices, which previously posed a significant transport barrier due to
their thickness. By leveraging brain-on-a-chip systems, researchers can now achieve
a more in vivo-like environment, while preserving cell viability and the native
tissue architecture found in thicker slices. This innovative combination of
microfluidic devices, organotypic slices, and brain-on-a-chip technologies has
opened up new avenues for studying complex neural networks, exploring drug
responses, and advancing our understanding of brain function. These
advancements hold great promise for unlocking the secrets of the brain and
developing novel therapeutic strategies for neurological disorders.
Segmental Insights
Type Insights
Based on the type, the market for organ-on-chip is
predominantly driven by the liver-on-chip model segment, and this trend is
expected to persist during the projected period (2024-2028). As the largest
internal organ in the human body, the liver plays a crucial role in the synthesis
and metabolism of various substances, including drug metabolites.
Modeling the liver has posed challenges due to its
diverse range of vital functions, encompassing nutrient and vitamin processing,
detoxification, and regulation of bodily metabolism. The limitations inherent
in conventional two-dimensional (2D) cell culture techniques for studying
pharmacokinetics in hepatic cells (hepatocytes) have yielded suboptimal
outcomes in clinical trials and drug development. Recent advancements in
microfluidics have facilitated the development of highly automated, biomimetic
liver-on-a-chip (LOC) devices that closely mimic the shape and function of the
natural liver. These LOC devices offer an economical and precise model for
pharmacodynamics, pharmacokinetics, and toxicity research. One noteworthy
example is the Emulate human Liver-Chip, which faithfully replicates the in
vivo physiological processes of the human liver through essential
microenvironmental factors such as 3D multicellular architecture and vascular
flow. With these characteristics, the Emulate human Liver-Chip provides a more
accurate representation of the human liver compared to conventional sandwich
cultures, animal models, and spheroids.
End User Insights
Based on the end user segment, the market is
categorized into Pharmaceutical and Biotechnology companies, Academic and
Research institutes, and Others, based on the end user. Among these, the
pharmaceutical and biotechnology sector significantly contributes to the
market. This technique holds immense potential for predicting side effects and
the success of drugs and biological products, particularly for the
pharmaceutical and biotech industries. The increasing rate of drug approval
failures necessitates the development of a comprehensive biological dataset to
assess innovative therapies and ensure the safety of novel treatments, where
Organ-on-Chip (OoC) technology plays a crucial role. Numerous pharmaceutical
and biotechnology firms are leveraging this technique to expedite the discovery
and development of novel medications. The market's growth is primarily driven
by the growing adoption of Organ-on-Chip technology for drug development by
enterprises.
Regional Insights
The North America region
is projected to dominate the global market share of organ-on-chip technology.
This can be attributed to several factors, including the presence of key
pharmaceutical companies, the availability of advanced organ-on-chip models,
and favorable government initiatives in terms of funding and programs for drug
development and research. The region is also witnessing an increase in targeted
diseases such as UI, bladder blockage, urine retention, BPH, and bladder
cancer, which further drives the market. Conversely, the Asia Pacific region is
expected to experience the fastest growth during the forecast period. Countries
like China, India, and Japan present attractive opportunities due to the rising
disposable income and increasing adoption of Organ-on-a-Chip technology.
Government support for regenerative medicines, along with investments in
R&D activities and cell-based clinical trials, are expected to facilitate
the expansion of the Organ-on-a-Chip market in the Asia-Pacific region.
Download Free Sample Report
Recent Developments
- In June 2023, MatTek Life Sciences announced a
strategic partnership with AIM Biotech, facilitating the availability of AIM
Biotech's portfolio for sale through MatTek.
- In June 2023, Emulate introduced Emulate Chip-A1™,
expanding its applications in the cancer and cosmetic markets.
- In May 2022, Emulate enhanced its intestinal
organ-on-a-chip to support researchers studying inflammatory bowel disease.
-
In April 2022, Valo Health completed the acquisition of TARA Biosystems, the
creators of a 3D heart tissue modeling platform. Valo planned to integrate
TARA’s heart tissue chips into an end-to-end drug development offering
targeting cardiovascular disease, leveraging its Opal data platform.
Key
Market Players
- Altis Biosystems
- AxoSim Inc.
- BiomimX SRL
- Emulate Inc.
- Hesperos
- Allevi Inc.
- InSphero AG
- MIMETAS BV
- Nortis Inc.
- Hesperos, Inc.
|
By
Type
|
By
Offering
|
By
Material Type
|
By
Application
|
By
End User
|
By
Region
|
|
|
Liver
Heart
Lung
Kidney
Others
|
Products
Services
|
Polymer
PDMS
Glass
Silicon
Others
|
Physiological
Model Development
Drug
Discovery
Toxicological
Research
Molecular
Biology
Others
|
Hospital
& Clinic
Home
Care
Ambulatory
Surgical Center
|
North
America
Europe
Asia
Pacific
South
America
Middle
East & Africa
|
Report
Scope:
In this report, the Global
Organ-on-Chip Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Organ-on-Chip Market, By Type:
o
Liver
o
Heart
o
Lung
o
Kidney
o
Others
- Organ-on-Chip Market, By Offering:
o
Products
o
Services
- Organ-on-Chip Market, By Material Type:
o
Polymer
o
PDMS
o
Glass
o
Silicon
o
Others
- Organ-on-Chip Market, By Application:
o
Physiological Model
Development
o
Drug Discovery
o
Toxicological
Research
o
Molecular Biology
o
Others
- Organ-on-Chip Market, By End User:
o
Hospital & Clinic
o
Home Care
o
Ambulatory Surgical
Centre
- Organ-on-Chip Market, By Region:
o North
America
§ United
States
§ Canada
§ Mexico
o Europe
§ France
§ United
Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South
Korea
o South
America
§ Brazil
§ Argentina
§ Colombia
o Middle
East & Africa
§ South
Africa
§ Saudi
Arabia
§ UAE
Competitive
Landscape
Company
Profiles: Detailed analysis of the major companies present in
the Global Organ-on-Chip Market.
Available
Customizations:
Global Organ-on-Chip market
report with the given market data, Tech Sci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company
Information
- Detailed
analysis and profiling of additional market players (up to five).
Global Organ-on-Chip
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]